样式: 排序: IF: - GO 导出 标记为已读
-
In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM) Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-24 Barbara A. Brown-ElliottGeorgie BushM. Dolores HughesEliana RodriguezChase A. WeikelSharon B. MinRichard J. Wallace1The University of Texas Health Science Center at Tyler, Mycobacteria/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA2Department of Infectious Diseases, GSK, Collegeville, Pennsylvania, USA, Jared A. Silverman
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-24 Laura Butragueño-Laiseca, Iñaki F. Troconiz, Santiago Grau, Nuria Campillo, Belén Padilla, Sarah Nicole Fernández, María Slöcker, Laura Herrera, María José Santiago
Meropenem is commonly prescribed in critically ill children for targeted therapy in severe and multidrug-resistant bacterial infections. Meropenem, as a carbapenem, has a time-dependent bactericidal effect. Optimal dosing is evaluated based on the ability to maintain meropenem concentrations in plasma above the minimum inhibitory concentration (MIC) of the infecting pathogen throughout the dosing interval
-
Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-24 Qian Tong, Chengqiang Yin, Xudong Hang, Yuefan Bai, Chongwen Zhang, Jingcheng Xu, Yan Huang, Yixin Ge, Tianyu Chen, Liping Zeng, Jia Jia, Hongkai Bi
Helicobacter pylori is a Gram-negative spiral-shaped and transmissible human pathogen that infects the stomach of ~50% of the world population (1). Since the discovery of H. pylori by Marshall and Warren in the early 1980s (2), it has been proven to cause chronic gastritis and to increase the risk of peptic ulceration, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma (3). The
-
Altered serine metabolism promotes drug tolerance in Mycobacterium abscessus via a WhiB7-mediated adaptive stress response Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-23 Célia Bernard, Yi Liu, Gérald Larrouy-Maumus, Christophe Guilhot, Kaymeuang Cam, Christian Chalut
Treatment failure of bacterial infections is mostly associated with intrinsic and acquired bacterial resistance. However, beyond bacterial resistance, drug tolerance has significant clinical implications in the management of chronic infections since it contributes to the extended duration of antibiotic treatment (1). Tolerance is an adaptive trait that relies on the ability of a whole bacterial population
-
Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-22 Size LiXu ZhuGuoying CaoJufang ShenXu ZhuJicheng YuXiaojie WuJufang WuHaijing YangNanyang LiYingying HuJingjing WangHaihui HuangJing Zhang1Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China2Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China3Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission, Shanghai
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Ensuring a sustained workforce to combat antibiotic resistance in the 21st century: the critical need for training the next-gen of scientists at the pre-doctoral level Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-19 William M. Shafer, Graeme L. Conn
Applebaum remarked in 2012 on the potential for the start of a second pre-antibiotic era (1). Along with other recommendations to avoid this horrific scenario, he emphasized that “a start must also be made in educating the next generation in research on antibacterial susceptibility and resistance.” This need is now even more acute with the departure of many “Big Pharma” companies from the antibiotic
-
Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-19 Angélica M. Rosado-Quiñones, Emilee E. Colón-Lorenzo, Zarna Rajeshkumar Pala, Jürgen Bosch, Karl Kudyba, Heather Kudyba, Susan E. Leed, Norma Roncal, Abel Baerga-Ortiz, Abiel Roche-Lima, Yamil Gerena, David A. Fidock, Alison Roth, Joel Vega-Rodríguez, Adelfa E. Serrano
Malaria continues to be one of the leading causes of death from infectious diseases in endemic areas worldwide, with 247 million cases and 619,000 deaths in 2021 (1). The emergence of multidrug-resistant Plasmodium falciparum has significantly worsened the global malaria burden, with increasing incidence and mortality rates (2). Antimalarial monotherapies like chloroquine (CQ) (3–7) and artemisinin
-
Correction for Chen et al., “Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination” Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-16 Tianyu ChenJing YaoKeao QuanJingchen XuXudong HangQian TongGenyan LiuPeipei LuoLiping ZengGanzhu FengHongkai Bi
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Possibility of hypoalbuminemia itself as a risk for clinical failure Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-17 Shougen Sumiyoshi, Shungo Yamamoto
We appreciate the efforts of Arensman Hannan et al. in conducting an interesting study (1). They reported that patients with hypoalbuminemia were associated with a lower proportion of clinical success among patients with obesity who were treated with ceftriaxone. They concluded that the presence of hypoalbuminemia may result in suboptimal drug exposure because ceftriaxone is a highly protein-bound
-
Genomic characterization of ST38 NDM-5-producing Escherichia coli isolates from an outbreak in the Czech Republic Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-16 Katerina Chudejova, Tsolaire Sourenian, Jana Palkovicova, Katarina Stredanska, Lucie Nechutna, Katerina Vlkova, Vendula Studentova, Jaroslav Hrabak, Costas C. Papagiannitsis, Monika Dolejska, Ibrahim Bitar
During an ongoing nationwide genomic surveillance of carbapenemase-producing Enterobacterales in the Czech Republic, a high number of NDM-5-producing Escherichia coli isolates belonging to the sequence type 38 (ST38) have been identified in Brno. Therefore, the study aims to investigate this outbreak and characterize these strains on a genomic level to understand the features that makes this clone
-
Inactivation of the ribosome assembly factor RimP causes streptomycin resistance and impairs motility in Salmonella Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-17 Zhihui LyuYunyi LingAmbro van HoofJiqiang Ling1Department of Cell Biology and Molecular Genetics, The University of Maryland, College Park, Maryland, USA2Department of Microbiology and Molecular Genetics, The University of Texas Health Science Center at Houston, Houston, Texas, USA, Boudewijn L. de Jonge
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-16 Sophie HartuisIsabelle Ourliac-GarnierEstelle RobertMarjorie AlbassierLéa DuchesneClara BeaufilsJoséphine KuhnPatrice Le PapeFlorent Morio1Nantes Université, CHU Nantes, Cibles et Médicaments des Infections et de l'Immunité, Nantes, France2Nantes Université, Cibles et Médicaments des Infections et de l'Immunité, Nantes, France3Department Public Health, Nantes Université, CHU Nantes, Nantes, France
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-15 Hanna Helena Schalkwijk, Neesha Rajesh Shewakramani, Kalyan Das, Graciela Andrei, Robert Snoeck
Herpes simplex virus 1 (HSV-1) is a common cause of acute and recurrent ophthalmic disease, predominantly manifesting as herpetic keratitis (1). Ocular HSV-1 infections are an important cause of infectious blindness, mostly due to their recurrent nature (2). Antiviral prophylaxis with the nucleoside analog acyclovir (ACV) or its prodrug valacyclovir is often used to reduce the burden of recurrent herpetic
-
Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-β-lactamase (blaVIM): infection management and molecular analysis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-11 Ana D. VegaKailynn DeRondeAdriana JimenezMichael PiazzaChristine VuOctavio MartinezLaura J. RojasSteven MarshallMohamad YasminRobert A. BonomoLilian M. Abbo1Department of Pharmacy, Jackson Health System, Miami, Florida, USA2Department of Epidemiology, Florida International University, Miami, Florida, USA3Department of Medicine, Virtua Medical Group, Medford, New Jersey, USA4Department of Medicine,
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-12 Breanne Mefford, Katie L. Wallace, J. Chris Donaldson, Brittany D. Bissell Turpin, Parijat Sen, Aric D. Schadler, Lucas J. Liu, Melissa L. Thompson Bastin
Early administration of appropriate antimicrobials is essential in reducing sepsis-related mortality (1). For patients with sepsis or septic shock at high risk of methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant organisms (MDR), a combination of piperacillin-tazobactam (TZP) or cefepime (FEP) or meropenem (MEM) and vancomycin (VAN) are frequently utilized. Recent evidence
-
Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma—en route to broad-spectrum antimycetomal drugs Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-11 Sami Ahmed KhalidShereen Abd AlgaffarNasir TajuddeenBlaise Kimbadi LombeGerhard Bringmann1Faculty of Pharmacy, University of Science and Technology, Omdurman, Sudan2Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria3Institute of Organic Chemistry, University of Würzburg, Würzburg, Germany4Faculty of Sciences, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, Audrey Odom
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Comparison of lumefantrine, mefloquine, and piperaquine concentrations between capillary plasma and venous plasma samples in pregnant women with uncomplicated falciparum and vivax malaria Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-10 Makoto Saito, Pornpimon Wilaisrisak, Mupawjay Pimanpanarak, Jacher Viladpai-Nguen, Moo Kho Paw, Urairat Koesukwiwat, Joel Tarning, Nicholas J. White, Francois Nosten, Rose McGready
Capillary blood samples are considered as a potential alternative to venous samples for assessing drug concentrations. In resource-limited settings, capillary samples are preferred because they are less expensive, easier to obtain, and less invasive than venous samples, especially in small children. In malaria clinical trials, capillary samples have the additional advantage that capillary samples are
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-10 Allan Kengo, Firdaus Nabeemeeah, Paolo Denti, Ryan Sabet, Gifty Okyere-Manu, Pattamukkil Abraham, Lubbe Weisner, Modiehi Helen Mosala, Sibongile Tshabalala, Janine Scholefield, Juan Eduardo Resendiz-Galvan, Neil A. Martinson, Ebrahim Variava
The surge in the incidence of rifampicin/drug-resistant tuberculosis (DR-TB) is an obstacle to global efforts to eradicate TB (1). Unlike its susceptible form, DR-TB is more challenging to manage and requires a longer treatment duration (2). However, new regimens utilizing novel and repurposed antimycobacterial agents have greatly reduced treatment duration (3) and mortality attributed to DR-TB (4)
-
Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-10 Andrew S. Haynes, Zixuan Wei, Peter Anderson, Marc H. Scheetz, Sarah K. Parker, Douglas N. Fish
Musculoskeletal infections in children, including acute hematogenous osteomyelitis and septic arthritis, are among the most common severe infections affecting children. Staphylococcus aureus is the most common bacterial etiology, with most isolates remaining methicillin-susceptible S. aureus (MSSA) throughout the United States (1). The current standard of care for treating pediatric musculoskeletal
-
The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-09 Julien LossouarnElsa BeurrierAstrid BouteauElisabeth MoncautMaria Sir SilmaneHeïdi PortalierAsma ZouariVincent CattoirPascale SerrorMarie-Agnès Petit1Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France2CHU de Rennes, Service de Bactériologie-Hygiène Hospitalière et CNR de la Résistance aux Antibiotiques (laboratoire associé "Entérocoques"), Rennes, France3Université
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Influenza C virus susceptibility to antivirals with different mechanisms of action Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-08 Anton Chesnokov, Andrei A. Ivashchenko, Yoko Matsuzaki, Emi Takashita, Vasiliy P. Mishin, Alexandre V. Ivachtchenko, Larisa V. Gubareva
Influenza viruses of type A, B, and C are known to cause respiratory infections in humans. While influenza B viruses are predominantly human pathogens, influenza A viruses have a vast reservoir in nature and pose an ongoing pandemic threat. Type C influenza viruses do not cause seasonal epidemics but may cause outbreaks among humans, particularly in young children (1), and are also known to infect
-
Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-08 Peter Christensen, Rosy Cinzah, Rossarin Suwanarusk, Adeline Chiew Yen Chua, Osamu Kaneko, Dennis E. Kyle, Htin Lin Aung, Jessica Matheson, Pablo Bifani, Laurent Rénia, Gregory M. Cook, Georges Snounou, Bruce Russell
The second most prevalent human malaria species, Plasmodium vivax, is intractable to continuous growth in vitro (1), and consequently, little data are available on the interaction between or on the mode of action of drugs suitable to treat vivax malaria (2, 3). Apart from in vivo primate studies, ex vivo schizont maturation assays (SMA) remain the only method for investigating P. vivax antimalarial
-
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1 Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-08 Hardik ChandasanaRajendra SinghKimberly AdkisonMounir Ait-KhaledTeodora Pene Dumitrescu1Clinical Pharmacology Modeling & Simulation, GSK, Collegeville, Pennsylvania, USA2ViiV Healthcare, Durham, North Carolina, USA3ViiV Healthcare Ltd., Brentford, United Kingdom, Sean Wasserman
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-08 Husain Poonawala, Yu Zhang, Sravya Kuchibhotla, Anna G. Green, Daniela Maria Cirillo, Federico Di Marco, Andrea Spitlaeri, Paolo Miotto, Maha R. Farhat
The early diagnosis of tuberculosis (TB) and universal drug-susceptibility testing are essential components of the WHO’s END-TB strategy (1). Molecular diagnostics that rely on detecting targeted antibiotic resistance mutations in the Mycobacterium tuberculosis (Mtb) genome have been rapidly integrated into national TB programs and are currently standard-of-care (2–5). However, commercially available
-
Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-05 Riste Kalamees, Hiie Soeorg, Mari-Liis Ilmoja, Kadri Margus, Irja Lutsar, Tuuli Metsvaht
Vancomycin is widely used in neonatal intensive care units (NICUs) (1). The pharmacokinetics (PK) of vancomycin is highly variable because of developmental shifts and changing disease severity in neonates. With standard dosing regimens, the therapeutic goal of vancomycin trough concentration (Ctrough) 10–15 mg/L is achieved in <30% of neonates (2, 3), but in 71%–94% when applying model-informed precision
-
ABC transporter inhibition by beauvericin partially overcomes drug resistance in Leishmania tropica Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-04 Charbel Al KhourySergio ThoumiSima TokajianAia SinnoGeorges NemerMark El BeyrouthyKelven Rahy1Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon2Department of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon3Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon4Division
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-04 Tianlu Teng, Suting Chen, Fengmin Huo, Junnan Jia, Liping Zhao, Guanglu Jiang, Fen Wang, Naihui Chu, Hairong Huang
Mycobacterium abscessus (M. abscessus) is a rapidly growing nontuberculous mycobacterium (NTM) that has been increasingly isolated in clinical settings in recent years. This rapidly growing microorganism consists of three subspecies, namely subsp. abscessus, subsp. bolletii, and subsp. massiliense (1). Pulmonary disease caused by M. abscessus is considered one of the hardest to treat successfully among
-
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK) Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-03 Alita A. MillerSamir H. MoussaSarah M. McLeod1Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA, Pranita D. Tamma
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-02 Hirokazu YanoWataru HayashiSayoko KawakamiSadao AokiEiko AnzaiHui ZuoNorikazu KitamuraAki HirabayashiToshiki KajiharaShizuo KayamaYo SugawaraKoji YaharaMotoyuki Sugai1Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan, Pranita D. Tamma
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
The Ptk2-Pma1 pathway enhances tolerance to terbinafine in Trichophyton rubrum Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-03 Masaki IshiiTsuyoshi YamadaKazuki IshikawaKoji IchinoseMichel MonodShinya Ohata1Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Tokyo, Japan2Teikyo University Institute of Medical Mycology, Teikyo University, Tokyo, Japan3Asia International Institute of Infectious Disease Control, Teikyo University, Tokyo, Japan4Department of Dermatology, Centre Hospitalier
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
A randomized assessors-blind clinical trial to evaluate the safety and the efficacy of albendazole alone and in combination with mebendazole or pyrantel for the treatment of Trichuris trichiura infection in school-aged children in Lambaréné and surroundings Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-02 Paul Alvyn Nguema MoureMoustapha Nzamba MaloumGédéon Prince ManouanaRoméo-Aimé Laclong LontchiMirabeau Mbong NgweseJean Ronald EdoaJeannot Fréjus ZinsouBrice MeulahSaidou MahmoudouElsy Mirna N'noh DansouYabo Josiane HonkpehedjiBayode Romeo AdegbiteSelidji Todagbe AgnandjiMichael RamharterBertrand LellSteffen BorrmannPeter G. KremsnerJean Claude Dejon-AgobéAyôla Akim Adegnika1Centre de Recherches Médicales
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Acinetobacter baumannii international clone 2 co-producing OXA-23, NDM-1, and ArmA emerging in South America Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-01 Thais Martins-Gonçalves, Julia S. Pimenta, Herrison Fontana, Fernanda Esposito, Gregory Melocco, Karine Dantas, Felipe Vásquez-Ponce, Floristher E. Carrara, Eliana C. Vespero, Nilton Lincopan
Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. The clinical significance of A. baumannii lies in its ability to acquire multiple resistance determinants resulting in difficult-to-treat infections (1). In this regard, carbapenem-resistant A. baumannii are in the top position of “the WHO priority pathogens”, for which novel antibiotics are needed (2). In South
-
In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-01 Liang ChenElena ShashkinaNatalia KurepinaVinicius Calado Nogueira de MouraCharles L. DaleyBarry N. Kreiswirth1Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA2Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA3Department of Medicine, National Jewish Health, Denver, Colorado, USA4The University of Colorado, Aurora,
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-04-01 Teclegiorgis Gebremariam, Sondus Alkhazraji, Yiyou Gu, Laura K. Najvar, Katyna Borroto-Esoda, Thomas F. Patterson, Scott G. Filler, Nathan P. Wiederhold, Ashraf S. Ibrahim
Mucormycosis is a highly aggressive and lethal fungal infection in immunocompromised hosts, such as neutropenic patients, patients undergoing hematopoietic cell or solid organ transplant, or patients receiving corticosteroids (1–4). In addition, individuals with poorly controlled diabetes in diabetic ketoacidosis (DKA) are also at risk. The overall mortality rate of this invasive mycosis is greater
-
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-29 Michael R. HodgesSusan HazelWilliam G. KramerEwoud-Jan van HoogdalemSjoerd van MarleMargaret TawadrousAbhijeet Jakate1Amplyx Pharmaceuticals, Inc., San Diego, California, USA2Pfizer Inc., New York, New York, USA3Kramer Consulting LLC, North Potomac, Maryland, USA4ICON, Groningen, the Netherlands, Andreas H. Groll
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Population-specific variations in KCNH2 predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-28 Mahamadou D. CamaraYitian ZhouAntoine DaraMamadou M. TékétéTaís Nóbrega de SousaSékou SissokoLaurent DembéléNouhoun OuologuemAmadou Hamidou TogoMohamed L. AlhousseiniBakary FofanaIssaka SagaraAbdoulaye A. DjimdePedro J. GilVolker M. Lauschke1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden2Department of Epidemiology of Parasitic Diseases, Malaria Research and Training
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Reply to Cossu et al., “Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV” Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Kelong Han1Clinical Pharmacology Modeling & Simulation, GSK, Collegeville, Pennsylvania, USA, James E. Leggett
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Praharshinie Rupasinghe, Azka Ashraf, Nadia Barreda, Shafiqua Parveen, Muhammad Zubair, Roger Calderon, Sunil Asif, Nilma Hirani, Layila Chingisova, Atang Bulane, Pham Thu Hang, Doan Thu Ha, Elisa Ardizzoni, Nazia Kursheed, Willem Bram De Rijk, Leen Rigouts, Lorenzo Guglielmetti, Carol Mitnick, Bouke C. de Jong
Rifampicin plays a pivotal role in the first-line treatment of tuberculosis. Mutations in the rpoB gene confer varying levels of rifampicin resistance (1). Historically, phenotypic drug susceptibility testing based on bacilli growth in media containing the critical concentration (CC) of rifampicin was considered the gold standard for detecting rifampicin resistance. CC is the lowest concentration of
-
Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Maria Vittoria CossuAntonio D'AvolioCristina GervasoniAndrea GiacomelliDario CattaneoDavide Moschese1Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy2Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy, James E. Leggett
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19 Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Lindsay E. CleggOleg StepanovHenning SchmidtWeifeng TangHuixia ZhangChris WebberTaylor S. CohenMark T. EsserMats Någård1Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA2Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom3IntiQuan
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Exploring the links between SOS response, mutagenesis, and resistance during the recovery period Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Sreyashi Ghosh, Mehmet A. Orman
Mutagenesis is crucial from an evolutionary perspective as it introduces genetic diversity within populations, serving as a driving force for adaptation and survival. It creates the potential for advantageous traits that enhance the ability of an organism to survive in changing environments (1, 2). For instance, through mutations, bacteria can acquire genetic changes, conferring resistance to antimicrobial
-
In vitro activity of omadacycline against clinical isolates of Nocardia Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-27 Jonathan Pham, Russell J. Benefield, Natali Baker, Shane Lindblom, Nicholas Canfield, Carlos A. Gomez, Mark Fisher
Nocardia species are a diverse group of ubiquitous, aerobic, partially acid-fast, filamentous, Gram-positive bacilli (1–3). There are more than 100 recognized Nocardia species; approximately half are known human pathogens (4–6). Infections occur predominantly in patients with impaired cell-mediated immunity, typically via inhalation from the environment, and most frequently manifest as respiratory
-
Updated antimicrobial dosing recommendations for obese patients Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Ana Castro-Balado, Iria Varela-Rey, Beatriz Mejuto, Cristina Mondelo-García, Irene Zarra-Ferro, Teresa Rodríguez-Jato, Anxo Fernández-Ferreiro
Obesity, classified as a body mass index (BMI) ≥ 30 kg/m2, is now considered to be one of the most important public health problems. According to the World Health Organization (WHO), in 2016, approximately 2 billion adults were overweight, of which 650 million were affected by obesity (1). If current trends continue, it is estimated that by 2025, 2.7 billion adults will be overweight, more than 1 billion
-
Role of amino acid 159 in carbapenem and temocillin hydrolysis of OXA-933, a novel OXA-48 variant Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Mariam Rima, Saoussen Oueslati, Garance Cotelon, Elodie Creton, Rémy A. Bonnin, Laurent Dortet, Bogdan I. Iorga, Thierry Naas
Carbapenemase-producing Enterobacterales constitute a serious health issue limiting the therapeutic options for gram-negative bacterial infections and increasing the morbidity and mortality rates among patients (1). Carbapenemases belong to three molecular classes of ß-lactamases (1, 2). Classes A and D correspond to serine-active ß-lactamases and class B enzymes are metallo-ß-lactamases that require
-
In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Mariana CastanheiraJohn H. KimbroughJill LindleyTimothy B. DoyleJessica M. EwaldHelio S. Sader1JMI Laboratories, North Liberty, Iowa, USA2The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA, Alessandra Carattoli
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Jeffrey B. LockeChris M. PillarMariana CastanheiraCecilia G. CarvalhaesDavid AndesJalal A. AramChristina AndrzejewskiKen BartizalAnita F. DasTaylor SandisonGeorge R. ThompsonPeter G. Pappas1Cidara Therapeutics, Inc., San Diego, California, USA2Science and Operations, Microbiologics, Kalamazoo, Michigan, USA3JMI Laboratories, North Liberty, Iowa, USA4Department of Medicine, University of Wisconsin-Madison
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Quorum-sensing regulation of phenazine production heightens Pseudomonas aeruginosa resistance to ciprofloxacin Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Lexin Xia, Yue Li, Yufan Wang, Hui Zhou, Ajai A. Dandekar, Feng Xu, Meizhen Wang
With the wide use of antibiotics in clinical, agricultural, and industrial settings, many bacteria have developed antimicrobial resistance rapidly over the past several decades. It has been estimated that antimicrobial resistance currently causes 700,000 deaths per year, and it will cause a 2%–3.5% reduction in Gross Domestic Product by 2050 (1). Therefore, the World Health Organization has declared
-
Infection and antibiotic-associated changes in the fecal microbiota of C. rodentium ϕstx2dact-infected C57BL/6 mice Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Sabrina Mühlen, Ann Kathrin Heroven, Bettina Elxnat, Silke Kahl, Dietmar H. Pieper, Petra Dersch
Understanding the impact of antibiotic treatment on EHEC infections is crucial for appropriate clinical care. While discouraged by early studies, recent findings suggest certain antibiotics can impede disease progression. Here, we investigated the impact ...
-
Preventive nasal administration of flagellin restores antimicrobial effect of gentamicin and protects against a multidrug-resistant strain of Pseudomonas aeruginosa Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Ana Raquel MaiaAdeline CezardDelphine FouquenetVirginie VasseurBenoit BriardJean-Claude SirardMustapha Si-TaharVirginie Hervé1INSERM, Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France2Université de Tours, Faculté de Médecine, Tours, France3Université Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR8204 – CIIL – Center for Infection and Immunity of Lille
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-25 Xiao-Jian Zhou, Jason Lickliter, Maureen Montrond, Laura Ishak, Keith Pietropaolo, Dayle James, Bruce Belanger, Arantxa Horga, Janet Hammond
Dengue is a mosquito-borne illness caused by four serotypes of dengue virus (DENV1–4) (1). DENV belongs to the Flaviviridae family and is a single-stranded positive-sense RNA virus (1). Dengue virus-associated diseases are major causes of illness and death in the tropical and subtropical world, with an estimated 100–400 million people infected yearly (https://www.who.int/news-room/fact-sheets/deta
-
A nanochitosan-D-galactose formulation increases the accumulation of primaquine in the liver Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-22 F. GomesA. C. RibeiroG. S. SanchesH. S. BorgesL. A. U. TakahashiC. T. Daniel-RibeiroA. C. TedescoJ. W. L. NascimentoL. J. M. Carvalho1Laboratory of Malaria Research, Oswaldo Cruz Institute (IOC/Fiocruz), Reference Center for Malaria Research, Diagnosis and Training, Rio de Janeiro, Brazil2Department of Pharmacology (LaFaCE) - ICB, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Minas Gerais
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-22 Isabel M. BarcelóMaria Escobar-SalomGabriel CabotPau Perelló-BauzàElena Jordana-LluchBiel TaltavullGabriel TorrensEstrella Rojo-MolineroLaura ZamoranoAstrid PérezAntonio OliverCarlos Juan1Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain2Microbiology Department, University Hospital Son Espases (HUSE), Palma, Spain3Centro de Investigación Biomédica en Red, Área Enfermedades Infecciosas
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-22 Daisuke SuzukiAki SakuraiMitsutaka WakudaMasahiro SuzukiYohei Doi1Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan2Anjo Kosei Hospital, Anjo, Aichi, Japan3Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan4Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Genomic analysis of inter-hospital transmission of vancomycin-resistant Enterococcus faecium sequence type 80 isolated during an outbreak in Hiroshima, Japan Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-20 Takaya Segawa, Kanako Masuda, Junzo Hisatsune, Kasumi Ishida-Kuroki, Yo Sugawara, Masao Kuwabara, Hideki Nishikawa, Takahiro Hiratsuka, Tatsuaki Aota, Yasuo Tao, Yoshimi Iwahashi, Kuniko Ueda, Kaori Mae, Ken Masumoto, Hiroki Kitagawa, Hitoshi Komatsuzawa, Hiroki Ohge, Motoyuki Sugai
Enterococci are commensal bacteria in the gastrointestinal tract of healthy individuals that can be nosocomial pathogens causing urinary tract infections, bacteremia, endocarditis, meningitis, and other infections in compromised hosts. Most enterococci isolated in clinical settings are Enterococcus faecium and Enterococcus faecalis, with E. faecium tending to be more multidrug-resistant than E. faecalis
-
Vancomycin heteroresistance caused by unstable tandem amplifications of the vanM gene cluster on linear conjugative plasmids in a clinical Enterococcus faecium Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-20 Lingyan SunHemu ZhuangMengzhen ChenYan ChenYiyi ChenKeren ShiYunsong Yu1Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China2Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, China3Institute of Laboratory Medicine, Zhejiang University, Hangzhou, China4Department of Respiratory and Critical Medicine
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Real-time measurements of ATP dynamics via ATeams in Plasmodium falciparum reveal drug-class-specific response patterns Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-19 Eric Springer, Kim C. Heimsch, Stefan Rahlfs, Katja Becker, Jude M. Przyborski
Malaria is a serious infectious disease and remains one of the greatest public health burdens for humankind. In 2022, an estimated 249 million cases occurred worldwide. Of these, around 608,000 people died, with the majority of victims being children under five. Of Plasmodium species, Plasmodium falciparum has the highest impact on global health, causing most infections as well as the deadliest form
-
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-19 M. A. LyonsA. Obregon-HenaoM. E. RameyA. A. BaumanS. PaulyK. RossmasslerJ. ReidB. KargerN. D. WalterG. T. Robertson1Department of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA2Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA3Consortium
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Metabolic mechanism and pharmacological study of albendazole in secondary hepatic alveolar echinococcosis (HAE) model rats Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-19 Chaoqun Li, Yaogang zhang, Mingquan Pang, Yong Zhang, Chunhui Hu, Haining Fan
Alveolar echinococcosis (AE) is a zoonotic parasitic disease resulting from human infection by the larval stage of the alveolar tapeworm, Echinococcus multilocularis. This larval stage originates in the liver and possesses exogenous and invasive growth characteristics, infecting the entire liver over the course of 5–10 years, similar to a tumor. This leads to it sometimes being referred to as “worm
-
A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-19 Cyrielle CoddeFlorence RivalsAlexandre DestereYeleen FromageMarc LabriffePierre MarquetClément BenoistLaure PonthierJean-François FaucherJean-Baptiste Woillard1Service de Maladies Infectieuses et Tropicales, CHU Dupuytren, Limoges, France2Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France3Service de Pharmacologie et Pharmacovigilance, CHU, Nice, France4Inserm
Antimicrobial Agents and Chemotherapy, Ahead of Print.
-
Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression Antimicrob. Agents Chemother. (IF 4.9) Pub Date : 2024-03-18 Celia Fernández-Rubio, Mercedes Rubio-Hernández, Verónica Alcolea, Aroia Burguete-Mikeo, Paul A. Nguewa, Silvia Pérez-Silanes
Selenium (Se) is an essential trace element that has been demonstrated to be involved in several pathological conditions, such as cancer and cardiovascular or thyroid diseases, due to its anti-inflammatory, pro-immune, and antioxidant properties (1–5). Most organic Se exerts its effects through its joining to the selenoprotein synthesis pathway as selenocysteine, a naturally occurring amino acid analog